Friday, January 21, 2022
More

    Latest Posts

    Novartis seeks FDA approval for COVID-19 treatment after positive data

    Novartis AG and Molecular Partners AG will report positive top-line data from the antiviral Covid-19 treatment ensovibep on Monday seeking rapid regulatory approval worldwide.

    The results of a phase II study of 407 patients who received a single intravenous dose of Ensobibep showed a 78% reduction in Covid-19-related hospitalization or emergency room visits compared to placebo. , Showed an improvement in time to clinical recovery. Said.

    According to a Basel-based pharmaceutical company, Ensobibep treatment continues to maintain protection against previously identified variant of concern variants, including Omicron.

    Novartis
    NVS,
    + 1.16%

    November,
    + 0.61%

    He said he would exercise that option and pay CHF 150 million ($ 163.3 million) to license ensovibep from Molecular Partners.
    MOLN,
    -3.39%

    MOLN,
    + 28.82%

    Accelerate manufacturing scale-up.

    We also plan to first seek a rapid global regulatory permit through the US Food and Drug Administration’s Emergency Use Authorization.

    If approved, ensovibep will be the first multispecific antiviral molecule for the treatment of Covid-19, Novartis said.

    Write to Ed Frankle at edward.frankl@dowjones.com

    Novartis seeks FDA approval for COVID-19 treatment after positive data

    Source link Novartis seeks FDA approval for COVID-19 treatment after positive data

    The post Novartis seeks FDA approval for COVID-19 treatment after positive data appeared first on Eminetra.

    Latest Posts

    Don't Miss

    Stay in touch

    To be updated with all the latest news, offers and special announcements.